Evaluation of a mathematical model of diabetes progression against observations in the diabetes prevention program

American Journal of Physiology - Endocrinology and Metabolism

Volumn 303, Issue 2, 2012, Pages

  Hardy, Thomas ^a   Abu Raddad, Eyas ^a   Porksen, Niels ^a   De Gaetano, Andrea ^b  

^a ELI LILLY AND COMPANY   (United States)

^b CNR   (Italy)

Author keywords

Glucose; Insulin resistance; Insulin secretion; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE;

ARTICLE; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; INCIDENCE; INSULIN SENSITIVITY; MATHEMATICAL MODEL; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SIMULATION;

ADULT; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84863953295     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00421.2011     Document Type: Article

References (41)

1. Basu R, Breda E, Oberg AL, Powell CC, Dalla Man C, Basu A, Vittone JL, Klee GG, Arora P, Jensen MD, Toffolo G, Cobelli C, Rizza RA. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 52: 1738-1748, 2003.
2. Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 57: 24-31, 2008.
3. Bikman BT, Zheng D, Pories WJ, Chapman W, Pender JR, Bowden RC, Reed MA, Cortright RN, Tapscott EB, Houmard JA, Tanner CJ, Lee J, Dohm GL. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab 93: 4656-4663, 2008.
4. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol 24: 297-302, 2000.
5. Bonner-Weir S, Deery D, Leahy JL, Weir GC. Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 38: 49-53, 1989.
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.
7. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 54: 219-222, 2011.
8. De Gaetano A, Hardy T, Beck B, Abu-Raddad E, Palumbo P, Bue-Valleskey J, Porksen N. Mathematical models of diabetes progression. Am J Physiol Endocrinol Metab 295: E1462-E1479, 2008.
9. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 33: 313-343, 2006.
10. Defronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73: 1294-1301, 1991.
11. Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 26: 3102-3110, 2003.
12. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100: 1166-1173, 1997.
13. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, Defronzo RA. Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 292: E871-E883, 2007.
14. Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547: 192-199, 2006.
15. Haffner SM, D'Agostino R Jr, Festa A, Bergman RN, Mykkänen L, Karter A, Saad MF, Wagenknecht LE. Low insulin sensitivity [S(i) = 0] in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 26: 2796-2803, 2003.
16. Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol 96: 101-106, 2004.
17. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872, 1998.
18. Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 26: 2069-2074, 2003.
19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002.
20. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54: 1150-1156, 2005.
21. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50: 1683-1690, 2001.
22. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferatoractivated receptor-alpha in mice. Diabetologia 54: 339-349, 2011.
23. Mason CC, Hanson RL, Knowler WC. Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes 56: 2054-2061, 2007.
24. Mayer-Davis EJ, D'Agostino R Jr, Karter AJ, Haffner SM, Rewers MJ, Saad M, Bergman RN. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA 279: 669-674, 1998.
25. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, Defronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719, 2001.
26. Miyazaki Y, Matsuda M, Defronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25: 517-523, 2002.
27. Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, Ferrannini E. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 118: 51-57, 2005.
28. Panunzi S, De Gaetano A, Mingrone G. Advantages of the single delay model for the assessment of insulin sensitivity from the intravenous glucose tolerance test. Theor Biol Med Model 7: 9, 2010.
29. Pereira JA, Lazarin MA, Pareja JC, de Souza A, Muscelli E. Insulin resistance in nondiabetic morbidly obese patients: effect of bariatric surgery. Obes Res 11: 1495-1501, 2003.
30. Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 34: 1601-1604, 2011.
31. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 133: 92-103, 2000.
32. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform 35: 37-50, 2002.
33. Slentz CA, Tanner CJ, Bateman LA, Durheim MT, Huffman KM, Houmard JA, Kraus WE. Effects of exercise training intensity on pancreatic beta-cell function. Diabetes Care 32: 1807-1811, 2009.
34. Snitker S, Le KY, Hager E, Caballero B, Black MM. Association of physical activity and body composition with insulin sensitivity in a community sample of adolescents. Arch Pediatr Adolesc Med 161: 677-683, 2007.
35. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550-554, 1995.
36. Topp BG, Promislow K, deVries G, Miura RM, Finegood DT. A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. J Theor Biol 206: 605-619, 2000.
37. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12: 962-971, 2004.
38. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 15: 474-481, 2005.
39. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147: 1749-1753, 1987.
40. Zhou H, Isaman DJ, Messinger S, Brown MB, Klein R, Brandle M, Herman WH. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 28: 2856-2863, 2005.
41. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376: 103-111, 2010.